Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience
October 21 2019 - 7:05AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular
diagnostics and precision medicine, announced that it has named
Mark H. Pollack, M.D., chief medical officer of Myriad Neuroscience
effective Jan. 15, 2020. In this role, Dr. Pollack will lead
efforts to make GeneSight standard-of-care in clinical
practice. Dr. Pollack will report to Mark Verratti, president
of Myriad Neuroscience.
“We are excited to welcome Dr. Pollack to Myriad. During his
distinguished clinical career, Dr. Pollack has been on the
forefront of medical advances in treating people with mood and
anxiety disorders,” said Mr. Verratti. “He is joining us at a
pivotal time when we’re working to expand access to the GeneSight
test and ushering in a new era of precision medicine for people
with mental illness.”
Dr. Pollack is a board-certified psychiatrist with more than 30
years of experience in clinical psychiatry and neuroscience.
Most recently, he served as professor and chair of the Department
of Psychiatry at Rush University Medical Center in Chicago.
Prior to Rush, Dr. Pollack was a professor of psychiatry at Harvard
Medical School and director of the Center for Anxiety and Traumatic
Stress Disorders at Massachusetts General Hospital. He is
past president of the Anxiety and Depression Association of America
and served as chairman of its Scientific Advisory Board. Dr.
Pollack is recognized worldwide as an expert on mental illness,
lectures widely in national and international forums and has served
on numerous editorial, federal and industry advisory boards to
advance the field of psychiatry. He has published extensively
including more than 300 journal articles, five books and 39 book
chapters. Dr. Pollack received his medical degree from New
Jersey Medical School in Newark, NJ and his bachelor’s degree from
the University of Virginia in Charlottesville, Virginia.
“This is an exciting time to join Myriad Neuroscience as
combinatorial pharmacogenomics becomes the standard-of-care to help
guide physicians and improve care for people with depression,” said
Dr. Pollack. “I look forward to helping Myriad Neuroscience
advance the science and build upon the strong partnerships it has
with the healthcare providers, advocacy organizations and
payers.”
About GeneSight®
PsychotropicGeneSight Psychotropic is a
pharmacogenomic test that analyzes clinically important variations
in DNA. The results of the test can inform doctors about genes that
may affect how their patients metabolize or respond to depression
medications.
About Myriad GeneticsMyriad Genetics Inc., is a
leading precision medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
five critical success factors: building upon a solid
hereditary cancer foundation, growing new product volume, expanding
reimbursement coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate
2020. For more information on how Myriad is making a
difference, please visit the Company's website:
www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris,
ForeSight and Prequel are trademarks or registered trademarks of
Myriad Genetics, Inc. or its wholly owned subsidiaries in the
United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to expanding access to the GeneSight test;
making GeneSight standard-of-care in clinical practice; and the
Company's strategic directives under the caption "About Myriad
Genetics." These "forward-looking statements" are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by forward-looking statements. These risks and
uncertainties include, but are not limited to: the risk that sales
and profit margins of our molecular diagnostic tests and
pharmaceutical and clinical services may decline; risks related to
our ability to transition from our existing product portfolio to
our new tests, including unexpected costs and delays; risks related
to decisions or changes in governmental or private insurers’
reimbursement levels for our tests or our ability to obtain
reimbursement for our new tests at comparable levels to our
existing tests; risks related to increased competition and the
development of new competing tests and services; the risk that we
may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and pharmaceutical and
clinical services in a timely manner, or at all; the risk that we
may not successfully develop new markets for our molecular
diagnostic tests and pharmaceutical and clinical services,
including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying
our molecular diagnostic tests and pharmaceutical and clinical
services and any future tests and services are terminated or cannot
be maintained on satisfactory terms; risks related to delays or
other problems with operating our laboratory testing facilities and
our healthcare clinic; risks related to public concern over genetic
testing in general or our tests in particular; risks related to
regulatory requirements or enforcement in the United States and
foreign countries and changes in the structure of the healthcare
system or healthcare payment systems; risks related to our ability
to obtain new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire; risks related to our projections about our business,
results of operations and financial condition; risks related to the
potential market opportunity for our products and services; the
risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying
our tests; the risk of patent-infringement claims or challenges to
the validity of our patents or other intellectual property; risks
related to changes in intellectual property laws covering our
molecular diagnostic tests and pharmaceutical and clinical services
and patents or enforcement in the United States and foreign
countries, such as the Supreme Court decision in the lawsuit
brought against us by the Association for Molecular Pathology et
al; risks of new, changing and competitive technologies and
regulations in the United States and internationally; the risk that
we may be unable to comply with financial operating covenants under
our credit or lending agreements; the risk that we will be
unable to pay, when due, amounts due under our credit or lending
agreements; and other factors discussed under the heading "Risk
Factors" contained in Item 1A of our most recent Annual Report on
Form 10-K for the fiscal year ended June 30, 2019, which has been
filed with the Securities and Exchange Commission, as well as any
updates to those risk factors filed from time to time in our
Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. All information in this press release is as of the date
of the release, and Myriad undertakes no duty to update this
information unless required by law.
Media Contact: |
Ron Rogers |
|
Investor Contact: |
Scott Gleason |
|
(801) 584-3065 |
|
|
(801) 584-1143 |
|
rrogers@myriad.com |
|
|
sgleason@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024